病例报告:转移性乳腺癌患者发生唑来膦酸相关弥漫性眼眶炎症和葡萄膜炎的严重病例。
Case report: A severe case of zoledronate-associated diffuse orbital inflammation and uveitis in a patient with metastatic breast cancer.
发表日期:2024
作者:
Pushpinder Kanda, Isaura Guerrero-Córdova, Jobanpreet Dhillon, Adrian Tsang
来源:
Bone & Joint Journal
摘要:
唑来膦酸是一种维持骨骼健康的常用药物;然而,一种罕见的副作用包括眼部炎症。我们报告了一例转移性乳腺癌患者因输注唑来膦酸而同时出现前葡萄膜炎和眼眶炎症的病例。我们还进行了文献检索,以提供唑来膦酸相关眼部炎症病例的最新总结。这是一份带有文献综述的病例报告。使用 PubMed 与检索团队进行文献检索(时间线 2010 年至 2023 年):(唑来膦酸)AND(葡萄膜炎或巩膜炎或眼眶炎症或眼部炎症)。 一名 48 岁女性出现左眼疼痛、肿胀和视力下降接受唑来膦酸输注后 2 天视力。眼科检查显示非肉芽肿性前葡萄膜炎。 CT眼眶和眼部超声检查显示后巩膜炎和眼眶炎症的迹象。排除了感染或转移性癌症引起的眼部炎症。该患者接受了局部和全身皮质类固醇治疗。 2.5 周后炎症完全消退。眼眶炎症和葡萄膜炎是唑来膦酸的罕见副作用,但需要及时识别和治疗,以防止威胁视力的并发症。版权所有 © 2024 Kanda、Guerrero-Córdova、Dhillon 和 Tsang。
Zoledronate is a commonly prescribed medication to maintain bone health; however, a rare side effect includes ocular inflammation. We report a case of simultaneous anterior uveitis and orbital inflammation associated with zoledronate infusion in a patient with metastatic breast cancer. We also performed a literature search to provide an up-to-date summary of cases with zoledronate-associated ocular inflammation.This is a case report with literature review. Literature search (timeline 2010 to 2023) was performed using PubMed with the search team: (zoledronate) AND (uveitis OR scleritis OR orbital inflammation OR ocular inflammation).A 48-year-old female presented with left eye pain, swelling, and decreased vision 2 days after receiving zoledronic acid infusion. An ophthalmic exam showed non-granulomatous anterior uveitis. CT orbits and ocular ultrasound showed signs of posterior scleritis and orbital inflammation. Ocular inflammation caused by an infection or metastatic cancer was ruled out. The patient was treated with both topical and systemic corticosteroids. Complete resolution of the inflammation occurred after 2.5 weeks.Orbital inflammation and uveitis are an uncommon side effect of zoledronate but needs to be promptly recognized and treated to prevent sight-threatening complications.Copyright © 2024 Kanda, Guerrero-Córdova, Dhillon and Tsang.